ABSTRACT
Objetivo: Hay pocos estudios sobre las manifestaciones osteomusculares tras un trasplante alogénico de progenitores hematopoyéticos (TPH-ALO). El objetivo del presente estudio es investigar los síntomas osteomusculares observados tras la realización de un TPH-ALO como tratamiento de distintas enfermedades hematológicas y no hematológicas. Material y métodos: Estudio observacional retrospectivo, realizado mediante la revisión de historias clínicas. Resultados: Desde el año 1996 hasta el 2000 se identificó a 123 pacientes sometidos a un TPH-ALO, 34 niños (5 meses-14 años) y 81 adultos (15-55 años). La distribución por sexos fue la siguiente: 48 mujeres (39%) y 75 varones (61%). De estos pacientes, 43 (34,90%) presentaron enfermedad del injerto contra el huésped (EICH) aguda, 33 de 106 (31,1%) presentaron EICH crónica y 50 de los pacientes (40,65%) murieron durante el seguimiento. Catorce (13,2%) presentaron manifestaciones osteomusculares: 6 (5,6%) necrosis aséptica, 5 (4,7%) esclerodermia, uno artralgias y bronquiolitis obliterante, uno poliartralgias y otro monoartritis de rodilla. Conclusiones: Es difícil atribuir los síntomas osteomusculares tras un TPH-ALO a una sola causa. Las manifestaciones inflamatorias y fibrosantes pueden ocurrir debido al proceso inflamatorio de la EICH crónica o por los tratamientos administrados durante el procedimiento(AU)
Introduction: Few studies have examined musculoskeletal manifestations after allogenic hematopoietic stem cell transplantation (AHSCT). Objective: To investigate the musculoskeletal symptoms observed after AHSCT for distinct hematological and non-hematological diseases. Material and methods: We performed a retrospective, observational study through review of medical records. Results: There were 123 patients who underwent AHSCT from 1996 to 2000: 34 children (aged 5 months-14 years) and 81 adults (aged 15-55 years). There were 48 women (39%) and 75 men (61%). Of these patients, 43 (34.90%) had acute graft-versus-host disease (aGVHD). Thirty-three out of 106 patients (31.1%) had chronic GVHD (cGVDH) and 50 patients (40.65%) died during follow-up. Musculoskeletal manifestations were found in 14 patients (13.2%): aseptic necrosis in six (5.6%), scleroderma in five (4.7%), arthralgia and bronchiolitis obliterans in one, polyarthralgia in one, and knee monoarthritis in one. Conclusions: Musculoskeletal manifestations after AHSCT cannot be attributed to a single cause. Inflammatory and fibrosing manifestations can be due to the inflammatory process of cGVHD or to the treatments administered during transplantation(AU)
Subject(s)
Humans , Male , Female , Infant , Child, Preschool , Child , Adolescent , Adult , Middle Aged , Hematopoietic Stem Cell Transplantation/adverse effects , Musculoskeletal Diseases/etiology , Hematologic Diseases/therapy , Retrospective Studies , Graft Rejection/complicationsABSTRACT
INTRODUCTION: Few studies have examined musculoskeletal manifestations after allogenic hematopoietic stem cell transplantation (AHSCT). OBJECTIVE: To investigate the musculoskeletal symptoms observed after AHSCT for distinct hematological and non-hematological diseases. MATERIAL AND METHODS: We performed a retrospective, observational study through review of medical records. RESULTS: There were 123 patients who underwent AHSCT from 1996 to 2000: 34 children (aged 5 months-14 years) and 81 adults (aged 15-55 years). There were 48 women (39%) and 75 men (61%). Of these patients, 43 (34.90%) had acute graft-versus-host disease (aGVHD). Thirty-three out of 106 patients (31.1%) had chronic GVHD (cGVDH) and 50 patients (40.65%) died during follow-up. Musculoskeletal manifestations were found in 14 patients (13.2%): aseptic necrosis in six (5.6%), scleroderma in five (4.7%), arthralgia and bronchiolitis obliterans in one, polyarthralgia in one, and knee monoarthritis in one. CONCLUSIONS: Musculoskeletal manifestations after AHSCT cannot be attributed to a single cause. Inflammatory and fibrosing manifestations can be due to the inflammatory process of cGVHD or to the treatments administered during transplantation.
ABSTRACT
No disponible
Subject(s)
Humans , Injections, Intra-Articular , Arthritis, Rheumatoid/drug therapy , Tumor Necrosis Factor-alpha/antagonists & inhibitorsSubject(s)
Infant, Newborn , Infant , Child, Preschool , Child , Adolescent , Adult , Humans , Male , Female , FibromaABSTRACT
Cervical smears and serum samples were obtained from 28 ABO compatible patients with carcinoma of the cervix (CaCx) in O to IV clinical stages. Serum IgG antibodies against autologous CaCx cells were detected by immunofluorescence reactions in 24/24 patients with carcinoma of the cervix in I to IV clinical stages. These antibodies also reacted against alogeneic CaCx cells 53/54. Negative reactions were obtained n 4/4 cases of carcinoma of the cervix in stage O, and in control group, 10 normal persons and in 33 neoplastic sera from patients with other malignancies. Hence, detection of serum antibodies against CaCx cells could be an additional tool for CaCx detection.
